HLS Therapeutics Inc. (TSX:HLS)
4.850
-0.030 (-0.61%)
Jul 8, 2025, 11:33 AM EDT
HLS Therapeutics Revenue
HLS Therapeutics had revenue of $12.62M USD in the quarter ending March 31, 2025, with 1.20% growth. This brings the company's revenue in the last twelve months to $56.77M, down -6.61% year-over-year. In the year 2024, HLS Therapeutics had annual revenue of $56.62M, down -10.23%.
Revenue (ttm)
$56.77M
Revenue Growth
-6.61%
P/S Ratio
1.89
Revenue / Employee
$617.05K
Employees
92
Market Cap
154.00M CAD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.62M | -6.46M | -10.23% |
Dec 31, 2023 | 63.07M | 1.61M | 2.61% |
Dec 31, 2022 | 61.47M | 1.46M | 2.43% |
Dec 31, 2021 | 60.01M | 3.90M | 6.95% |
Dec 31, 2020 | 56.11M | 1.95M | 3.60% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sienna Senior Living | 896.45M |
Green Thumb Industries | 1.64B |
dentalcorp Holdings | 1.58B |
Extendicare | 1.47B |
WELL Health Technologies | 990.34M |
Cronos Group | 179.08M |
Trulieve Cannabis | 1.71B |
Curaleaf Holdings | 1.89B |
HLS Therapeutics News
- 6 days ago - HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan - Benzinga
- 2 months ago - HLS Therapeutics reports Q1 results - Seeking Alpha
- 2 months ago - HLS Therapeutics Announces Q1 2025 Financial Results - Benzinga
- 4 months ago - HLS Therapeutics GAAP EPS of -$0.10, revenue of $15.5M misses by $0.2M - Seeking Alpha
- 4 months ago - HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid - Benzinga
- 8 months ago - HLS Therapeutics GAAP EPS of -$0.15 beats by $0.04, revenue of $14.08M misses by $6.42M - Seeking Alpha
- 11 months ago - HLS Therapeutics GAAP EPS of -$0.18, revenue of $14.52M - Seeking Alpha